Inlyta axitinib regulatory update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending Inlyta axitinib from Pfizer to treat advanced renal cell carcinoma (RCC) in patients who failed treatment with a first-line tyrosine kinase inhibitor (TKI) or a cytokine. The recommendation is contingent on Pfizer providing Inlyta at an undisclosed discount under a patient access scheme. The inhibitor of VEGF receptors 1, 2 and 3 is approved in the EU to treat advanced RCC after failure of prior treatment with Pfizer’s Sutent sunitinib, a receptor TKI, or a cytokine. The FAD is in line with draft guidance issued in March 2014. ...